Lion-CM CSI Div S$

Colombia Partners with 3PBIOVIAN to Develop First Domestic Biosimilar Cancer Drug

- Colombia's National Cancer Institute has partnered with 3PBIOVIAN to develop the country's first biosimilar monoclonal antibody for oncology treatment, marking a historic shift toward pharmaceutical independence. - The initiative aims to address Colombia's heavy dependence on imported biotechnological drugs and reduce costs for cancer treatments in a country recording over 117,000 new cancer cases annually. - The project involves full development from cell line creation to technology transfer, with manufacturing planned at Colombian facilities as part of a broader $365 million investment in biopharmaceutical infrastructure. - This collaboration represents a strategic step toward building Colombia's biotechnological sovereignty and potentially establishing the country as a regional hub for biosimilar production in Latin America.